Spago Nanomedical AB (publ) (STO:SPAGO)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.119
+0.005 (4.39%)
Apr 29, 2026, 2:10 PM CET
-43.33%
Market Cap 75.42M
Revenue (ttm) 4.82M
Net Income (ttm) -26.55M
Shares Out 661.57M
EPS (ttm) -0.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 142,008
Average Volume 217,069
Open 0.119
Previous Close 0.114
Day's Range 0.119 - 0.119
52-Week Range 0.084 - 0.460
Beta 1.24
RSI 52.67
Earnings Date May 6, 2026

About Spago Nanomedical AB

Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under preclinical development stage. The company wa... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 7
Stock Exchange Nasdaq Stockholm
Ticker Symbol SPAGO
Full Company Profile

Financial Performance

In 2025, Spago Nanomedical AB's revenue was 4.82 million, a decrease of -27.53% compared to the previous year's 6.65 million. Losses were -26.55 million, -18.32% less than in 2024.

Financial Statements

News

Spago Nanomedical AB Transcript: Life Science Summit 2025

A novel radiopharmaceutical platform is advancing clinical trials in Australia, showing promising tumor uptake and a favorable safety profile. The technology targets multiple tumor types, including rare cancers, and is supported by ongoing capital raising and plans for accelerated development.

5 months ago - Transcripts